Fig. 1: Transformation-acquired epigenetic signature mediating the cancer stem cell phenotype.
From: Emerging role of G9a in cancer stemness and promises as a therapeutic target
Misregulation of epigenetic modifiers is commonly observed in cancer and drives oncogenic reprogramming of healthy tissues cells (left) into CSCs (right). Therapeutic strategies targeting the CSC epigenome, via inhibition of key epigenetic regulators aim to block the biogenesis of CSC via cellular plasticity, to restore normal-like functions such as differentiation and apoptosis sensitivity.
